PDCD1 and non-small cell lung carcinoma: This hypothesis appears to be confirmed by clinical data, as NSCLC and MM—cancers known to have a high mutational load as a result to exposure to cigarette smoking and UVA radiation, respectively—are among the tumor types most responsive to PD-1 blockade.